RxDoctor Payments DataLook up a doctor →

Alyson Yashar, MD

Ophthalmology · Woodcliff Lake, NJNPI 1639252794

Payments from drug & device makers

$27,025in general payments, 2019–2025

Across 422 payments — averaging $64.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$3K
  • Johnson & Johnson Surgical Vision, Inc.$3K
  • AbbVie$2K
  • Bausch & Lomb Americas Inc.$2K
  • Sight Sciences, Inc.$2K
  • Alcon$2K
  • plus $13K from 42 others

What the payments were for

  • Travel & lodging$9704%
  • Food & beverage$25,97596%
  • Education$400%
  • Gifts$250%
  • Entertainment$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,025 in reported general payments places this provider in the 90th percentile of 583 ophthalmology providers in New Jersey.

See all ophthalmology providers in New Jersey

Medicare billing

Part B allowed, 2024
$466,906
Medicare patients
849
Services billed
4,615

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine60$63,909
LumiganBimatoprost98$46,641
XiidraLifitegrast30$40,755
RocklatanNetarsudil Mesylat/Latanoprost27$16,987
TyrvayaVarenicline Tartrate23$15,745
MieboPerfluorohexyloctane/Pf18$13,256
Cyclosporine17$11,607
CombiganBrimonidine Tartrate/Timolol17$10,280
TobradexTobramycin/Dexamethasone27$7,151
Travoprost42$6,818
Bromfenac Sodium16$3,119
Prednisolone Acetate71$2,965
Tobramycin-DexamethasoneTobramycin/Dexamethasone56$2,604
TafluprostTafluprost/Pf20$2,486
Brimonidine Tartrate15$1,885

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$2,468$120,830175 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$2,142$54,01048 claims
Aerie Pharmaceuticals, Inc.Rocklatan$350$16,98727 claims
Oyster Point Pharma, Inc.Tyrvaya$522$15,74523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 583 ophthalmology providers in New Jersey.

Other ophthalmology in Woodcliff Lake

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →